Passage Bio
Focus: Passage Bio is a Philadelphia-based gene therapy biotech focused on treating rare neurological and lysosomal storage disorders. The company is in early-stage development with a limited but potentially high-impact pipeline.
Profile data last refreshed 2d ago · AI intelligence enriched 1w ago
Open Jobs
0
About Passage Bio
AI assessmentNot HiringNo open roles listed right now. Follow Passage Bio to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
0/9 — Limited
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Confirmatory Testing
Acid Sphingomyelinase DeficiencyNatural History Study of Infantile and Juvenile GM1 Gangliosidosis (GM1) Patients
GM1 GangliosidosisHelp build intelligence for Passage Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.